What trials have examined RASi and ACEi to reduce kidney disease progression?
A fair number of trials have examined RASi as agents used to reduce kidney disease progression in people with and without high BP, and/or with and without diabetes. Similarly, at least 3 large trials (HOPE,163 ) examined ACEi as CV protective agents in people with and without high BP and included a minority with CKD.